



26 September 2023

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – Successful completion of retail component of Entitlement Offer

SomnoMed Limited ACN 003 255 221 (**SomnoMed** or the **Company**) is today pleased to announce the successful completion of the retail component (**Retail Entitlement Offer**) of its 1 for 3.82 fully underwritten accelerated non-renounceable entitlement offer (**Entitlement Offer**).

The Retail Entitlement Offer closed on Thursday, 21 September 2023.

Completion of the Retail Entitlement Offer represents completion of the second stage of the Company's capital raising announced on Thursday, 31 August 2023 to raise approximately \$15.5 million. The first stage of the capital raising, being the approximate \$2.5 million institutional placement and \$7.3 million institutional component of the Entitlement Offer (together, the **Institutional Entitlement Offer**), completed on Friday, 1 September 2023, as announced to the market by the Company on Monday, 4 September 2023.

The Retail Entitlement Offer provided eligible retail shareholders of the Company the opportunity to subscribe for 1 new fully paid ordinary share in the Company (**New Share**) for every 3.82 existing fully paid ordinary shares held in the Company as at 7:00pm (Sydney, Australia time) on Monday, 4 September 2023 (**Entitlement**), at a price of \$0.60 per New Share. Eligible retail shareholders who took up their Entitlement in full under the Retail Entitlement Offer were invited to apply for additional New Shares (**Additional New Shares**), with any scale-back at the absolute discretion of the Company. The Company confirms that all shareholders who applied for Additional New Shares will have their applications allotted in full.

The Company received valid applications from eligible retail shareholders for approximately 5.1 million New Shares (including Additional New Shares) under the Retail Entitlement Offer. The remaining approximately 4.4 million New Shares not taken up by eligible retail shareholders under the Retail Entitlement Offer have been allocated to TDM Growth Partners Pty Ltd (**TDM**), who acted as the sole sub-underwriter to the Retail Entitlement Offer. Including the shares allocated to TDM, the Retail Entitlement Offer raised a total of \$5.7 million. The participation of TDM in the Entitlement Offer will result in an increase to their shareholding to approximately 30.0%.

Settlement of the Retail Entitlement Offer is expected to occur on Wednesday, 27 September 2023, with the New Shares and Additional New Shares expected to commence trading on the ASX on Friday, 29 September 2023.

Wilson's Corporate Finance Limited acted as sole lead manager, bookrunner and underwriter to the Entitlement Offer.

The results of the Entitlement Offer highlight the recognition from shareholders of the long-term value in SomnoMed and a support for the initiatives of the Company.

Terry Flitcroft
Company Secretary
SomnoMed Limited

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution more than 810,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New Shares to be offered and sold in the Entitlement Offer have not been, and will not be, registered under the United States Securities Act of 1933 (the **U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States.

Accordingly, the New Shares may not be offered or sold to persons in the United States, unless they have been registered under the U.S. Securities Act, or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This announcement contains such statements that are subject to risk factors associated with an investment in SomnoMed.